Tuberculosis Vaccine Development

Progress, Challenges & Future Direction

Mark Hatherill
Director, South African Tuberculosis Vaccine Initiative
University of Cape Town
Pathogen, disease and unmet medical need

The Global Burden of TB

2 billion people latently infected with *M. tuberculosis*
5-10% infected people progress to disease

9 million new TB cases each year

1.5 million TB deaths each year

Equivalent to 20 passenger aircraft crashes each day
Pathogen, disease and unmet medical need

TB is transmitted by adults with cavitatory disease

HIV infected people carry greater burden of disease,
but are not responsible for increased transmission (paucibacillary disease)

Children are sentinels for transmission

Young children most vulnerable
Highest risk of progression from TB infection to active disease, and worst TB morbidity and mortality, compared to older children and adults
Pathogen, disease and unmet medical need

Estimated TB incidence rates, 2013

Highest per capita rates of new TB cases in low and middle income countries of Africa and Asia
Pathogen, disease and unmet medical need

Estimated TB incidence: top-ten countries, 2013

Largest absolute number of TB cases in Asia (India, China 35%)
Aging of the epidemic

Highest per capita incidence in Southern Africa (HIV and mining)
Incidence in Africa >2x global average incidence (126 per 100,000)
Pathogen, disease and unmet medical need

Average 3.5% of new TB cases multidrug resistant (MDR-TB)

Emerging threat to TB control
Treatment cost 15x DS-TB

Potential for new TB vaccines

Source: CDC
Pathogen, disease and unmet medical need

The global TB epidemic has peaked
TB incidence rate falling at 1.5% per year
Not fast enough to meet TB control goals

*HIV-associated TB deaths are classified as HIV deaths according to ICD-10.
Target for TB elimination: Annual incidence <1 case per million population by 2050

Would need 1,000-fold reduction in 35 years
20% annual reduction is faster than historical examples

Dye, Annu Rev Public Heath 2013
Pathogen, disease and unmet medical need

2014 World Health Assembly
“End TB Strategy”
Reduce TB deaths by 95% and new cases by 90% by 2035

Need optimal use of existing tools
PLUS
New tools to prevent new infection and progression to disease – including new vaccines

*Impact of effective Prevention of Disease TB vaccine follows (4)
**Vaccine development: background**

**Why BCG is not good enough**

Live attenuated M. bovis, first used in 1921

BCG protects against severe meningitic and miliary TB in infants and children (RR 0.15)
Billions of doses administered to infants since 1970’s

Offers only partial protection against pulmonary TB in children
Little or no protection against pulmonary TB in adults

*Meta-analysis, Mangtani CID 2014*
Vaccine development: background

BCG efficacy is variable
Protection against pulmonary TB ranges from substantial (RR 0.22) to lack of benefit (RR 1.05).

Average RR 0.5 (0.35 – 0.72)

Highest BCG protection against TB disease in infants, and MTB uninfected children (RR 0.26), compared to MTB infected and uninfected adults (RR 0.88)

Implications for efficacy of novel live mycobacterial vaccines in high TB burden countries where 50 – 80% adults are MTB infected.

Meta-analysis, Mangtani CID 2014
Vaccine development: background

We need a new TB vaccine that offers longstanding, consistent protection against all forms of TB disease to infants, children, and adults, including MTB infected and HIV infected persons

Is such a vaccine feasible?
Encouraging preclinical data from non-human primates

Humans control 90% of MTB infections

Longstanding MTB infection itself appears protective against new disease

Partial efficacy of BCG vaccine

Andrews CID 2012
Vaccine development: background

Challenges

Murine model does not mimic human pulmonary TB disease

Limited access to NHP model

Lack of immune correlate of protection

Role of CD4 T cell IFN-gamma response?
Human T cell epitopes of MTB are hyperconserved in co-evolution (does the T cell response benefit the pathogen?)

Can MTB infected adults in TB endemic countries be protected?

Comas Nature Genetics 2010
Infant TB vaccination
BCG replacement vs. BCG Prime and Boost strategies

New/BCG At Birth  New Vaccine Boost  Childhood TB Disease  Adult TB Disease

Long-lasting protection against all forms of TB disease

Exposure & Infection  Exposure & Infection

Pre-exposure Strategy
Vaccine development: background

**Fallout from MVA85A**
First infant TB vaccine efficacy trial in 50 years did not show added benefit compared to BCG alone
Preclinical data not convincing
Modest CD4 T cell responses in infants

(1) Shift towards TB vaccine strategy aimed at preventing TB in young adults to interrupt the epidemic

(2) Re-focus on upstream, pre-clinical data from NHP model to guide gating

(3) Progression only of ‘Best-in-Class’

→ clinical trial hiatus
Vaccine development: background

Adult vaccine strategy (40% VE and 5-year protection) greater impact on TB incidence than infant vaccine (80% VE and lifelong protection) by 2050

Adult vaccine likely to prevent more infant TB cases than an infant vaccine – due to reduction in transmission

Modeled impact of a new TB vaccine targeted at infants (D) or adolescents/adults (E)

Knight, PNAS 2014

*waves = mass campaigns
Adult TB vaccination
Prime and Boost strategy

BCG at birth
New Vaccine
TB Disease

Protection against PTB disease

Exposure & Infection
Exposure & Infection

Can MTB infected people be protected?
Potential blocking (live mycobacterial) or masking (<BCG) of vaccine effect

Post-exposure Strategy (MTB and NTM)
<table>
<thead>
<tr>
<th>Phase 1</th>
<th>Phase 2a</th>
<th>Phase 2b</th>
<th>Phase 3</th>
</tr>
</thead>
</table>
| Ad5 Ag85A  
McMaster, Canada | VPM 1002  
(live attenuated rBCG)  
SII, TBVI | M72+AS01E  
(MTB32A and MTB39A)  
GSK, Aeras | M. Vaccae  
(lysate)  
Anhui Zhifei Longcom |
| DAR-901  
(heat killed M. obuense)  
Dartmouth, Aeras | RUTI  
(lysate M. tuberculosis)  
Archivel Farma |         |         |
| ***TB/FLU-04L  
(live attenuated influenza,  
ESAT-6, Ag85A)  
RIBSP, Russia | H1 + IC31  
(ESAT-6, Ag85B)  
SSI, TBVI, Aeras |         |         |
| Aeras-402  
(Ag85A, Ag85B, TB10.4)  
Crucell, Aeras | *H4+IC31  
(Ag85B, TB10.4)  
Sanofi, Aeras |         |         |
| ****MVA85A, Oxford |         |         |         |
| ChAdOx1.85A  
(chimp adenovirus)  
Oxford  
****MVA85A, Oxford | H56+IC31  
(85B, ESAT-6, Rv2660c)  
SSI, Aeras |         |         |
| MTBVAC  
(live attenuated M. tuberculosis)  
BioFabri, TBVI | **ID93+GLA-SE  
(Rv2608, Rv3619, Rv3620,  
Rv1813)  
IDRI, Aeras |         |         |

**Prevention of Infection  
** Prevention of Recurrence  
*** Intranasal  
**** Also Aerosol
The ‘Shift to the Left’: Concepts, Macaques, & Portfolio Management

Current

- Potential products
  - Murre/pig challenge
  - NHP challenge (often optional)
  - CMC, Tox, Safety
    - Phase 1a with minimal immunogenicity
    - Phase 1b with minimal immunogenicity
    - Phase 2a
    - Community-wide Phase 2b
  - Go/no-go: ≥ BCG (0.5 log)

New

- Diverse vaccine concepts
- Hypothesis testing in relevant small animal model
- CMC, tox, safety
  - NHP challenge
  - NHP immune signature
- Go/no-go: >> BCG
  - Phase 1a
  - Phase 1b
  - Phase 2a
  - Combined human and NHP data
  - Go/no-go: Combined human and NHP data
  - Go/no-go: Plausibility of efficacy shown
  - Plausibility of efficacy shown
  - Community-wide Phase 2b

Source: Bill & Melinda Gates Foundation

Collaboration for TB Vaccine Discovery (CTVD)
Global TB Vaccine Partnership (GTBVP)
Vaccine development: background

Experimental Medicine Studies in Humans

Demonstration of Proof of Concept

Prevention of Disease (POD)
Prevention of Infection (POI)
Prevention of Recurrence* (POR)

Therapeutic Vaccination

*Adjunctive Therapeutic Vaccination
Vaccine development: background

The rationale for a Prevention of Infection (POI) vaccine

**Case-Control Studies**
Evidence that BCG vaccination provides (modest) protection against IGRA conversion

Meta-analysis of 14 retrospective case-control studies (n=3,855)
BCG protective
RR for MTB infection 0.81 (95% CI 0.71 - 0.92)

*Roy BMJ 2014*
healthy, BCG-vaccinated, HIV uninfected adolescents

*Excludes: ESAT-6 subunit vaccines and attenuated MTB vaccines until new IGRA licensed

**IGRA Design**

- **IGRA**
- **Vaccine* / Placebo**
- **IGRA -**
- **Correlates of risk**
- **6-monthly IGRA**
- **24 MONTHS**
- **Select for Phase III POD trials**
**Vaccine development: background**

**Challenges for a Prevention of Infection (POI) strategy**

**Scientific Challenges**
90% people control own MTB infection, never progress to TB disease

If *effective* POI vaccine prevented only this subset of MTB infections
→ no impact on epidemic

An *ineffective* POI vaccine, that did not protect against MTB infection, might protect against future progression to TB disease
→ major impact on epidemic

**Regulatory Challenges**
No gold standard for MTB infection
IGRA = measure of T cell response to MTB
Not adequate surrogate endpoint for disease

**Development Pipeline Challenges**
Excludes subunit and MTB vaccines containing IGRA antigens (ESAT-6)

**Implementation Challenges**
50-80% of individuals in TB endemic countries already MTB infected in high school
Vaccine development: background

Opportunities for a Prevention of Infection (POI) strategy

Rate of MTB infection (IGRA+) 10-fold greater than incidence of TB disease

Opportunity to conduct smaller, cheaper, faster human trials

Proof of concept → ‘green light’ expansion into POD efficacy trials

ClinicalTrials.gov NCT02075203

Evaluate safety, immunogenicity, and prevention of infection by BCG revaccination, or by the novel vaccine H4:IC31 (AERAS-404), compared to placebo, in 990 SA adolescents

Primary endpoint IGRA conversion from negative to positive

Will also evaluate sustained IGRA conversion and sensitivity to alternative threshold values
Rationale for a Prevention of Recurrence (POR) vaccine

TB patients (Rx completed, confirmed cured) have several-fold higher risk of subsequent TB disease than surrounding community

Recurrent TB disease = true relapse (reactivation) and reinfection

**Incidence recurrent TB 2-8%**

70-90% occurs within 12 months of TB treatment completion

**Direct Public Health Impact**
Modest impact on health services and MDR-TB control

**TB Vaccine Development**
Leverage high incidence to show proof of concept efficacy (small, but complex trials)

**TB Drug Development**
Therapeutic adjunct
Shorten treatment (Drug-Sensitive and MDR-TB)
Major public health impact
Pathway to true therapeutic indication...
POR Design

BCG vaccinated, HIV uninfected adults
Smear and culture + pulmonary TB

12 MONTH FOLLOW-UP

RELAPSE vs REINFECTION

Select for Phase III
POI/POD and/or therapeutic trials

Ideally power POR trial
for both relapse
(reactivation from latency) and reinfection
Challenges for a Prevention of Recurrence (POR) strategy

Is a POR vaccine feasible in TB patients?

No direct evidence from human studies
2 small safety & immunogenicity studies ongoing (subunit vaccines)

Setting a high immunological bar?

Indirect evidence from humans
*M. Vaccae*
Therapeutic (meta-analysis 54 studies)
Time to sputum smear conversion
CXR resolution

*Yang Plos ONE 2011*

**Therapeutic benefit in Cynomolgus macaques**

Therapeutic Immunization against *Mycobacterium tuberculosis* Is an Effective Adjunct to Antibiotic Treatment

Rhea N. Coler, Sylvie Berthelet, Samuel O. Pine, Mark T. Orr, Valerie Reese, Hillarie Plessner Windish, Charles Davis, Maria Kahn, Susan L. Baldwin, and Steven G. Reed
Infectious Disease Research Institute, Seattle, Washington
Vaccine development: pipeline

Most advanced BCG replacement candidates

**VPM-1002** in HIV exposed/unexposed newborns in SA

**MTBVAC** in MTB uninfected adults and newborns in SA

Safety equivalent to BCG
Immunogenicity in newborns TBC ...
Role in POI for MTB uninfected adolescents?

**To test efficacy...**
Regulatory and ethical challenges to replace newborn BCG in an infant efficacy trial in a TB endemic country
Vaccine development: pipeline

Most advanced boost vaccine candidates

M72+AS01E in Phase 2b POD in MTB infected adults in SA (n=3,500)

H4+IC31 in Phase 2 POI in MTB uninfected adolescents in SA (n=990)

H56+IC31 seeking funding for POI

ID93+GLA-SE seeking co-funding for POR

<table>
<thead>
<tr>
<th>Phase 1</th>
<th>Phase 2a</th>
<th>Phase 2b</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ad5 Ag85A McMaster</td>
<td>VPM 1002</td>
<td>M72+AS01E GSK, Aeras</td>
<td>M. Vaccce lysate Anhui Zhifei Longcom</td>
</tr>
<tr>
<td>DAR-901 (heat killed M. bovis)</td>
<td>RUTI (lysate M. tuberculosis)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dartmouth, Aeras</td>
<td>Archivel Farma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TB/FLU-041 (flu)</td>
<td>H5+IC31 SSI, TRV1, Aeras</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RIIISP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ad35 / MVA85A Crucell, Oxford</td>
<td>H4+IC31 Sanofi, Aeras</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ChAdDx1.BSA/MVA85A (chimpanzee adenovirus) Oxford</td>
<td>H56+HC31 SSI, Aeras</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTBvAC (live attenuated M. tuberculosis) BioFabri, TRV1</td>
<td>ID93+GLA-SE ID01, Aeras</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Key**
- **Viral vector**
- **Viral vector**
- **Mycobacterial whole cell extract**
- **Protein + adjuvant**

**Viral-vectored candidates**
Experimental medicine: MVA85A aerosol delivery

Advancement of H56+IC31 dependent on NHP studies and H4 POI

**Best in Class?**
Vaccine development: pipeline

Challenges for the pipeline

Limited number of concepts & vaccine classes

Candidates in ‘pipeline limbo’

NHP gating bottleneck

Fragmentation of efforts

POD - BCG replacement vs adult boost

POI and POR strategies untested, underfunded

Potential for therapeutic vaccination untapped

‘Shift to the left’

Limited funding options

<table>
<thead>
<tr>
<th>Phase 1</th>
<th>Phase 2a</th>
<th>Phase 2b</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ads Ag85A MidMaster</td>
<td>VPM 1002 (live attenuated BCG) SB, TBVI</td>
<td>M72+AS01E GSK, Aeras</td>
<td>M. Vaccae (lysat) Archui Zhifei Longcom</td>
</tr>
<tr>
<td>DAR-901 (heat killed M. bovis) Dartmouth, Aeras</td>
<td>RUTI (lysat M. tuberculosis) Archivel Farma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TB/FLU-04L (influenza) RIBSP</td>
<td>M1 + IC31 SSI, TBVI, Aeras</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ad35 / MVA85A Crucell, Oxford</td>
<td>M4+IC31 Sanioti, Aeras</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ChAdOx1.ASA/MVA85A (chimp adenovirus) Oxford</td>
<td>H56+IC31 SSI, Aeras</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTBVEC (live attenuated M. tuberculosis) Biofabri, TBVI</td>
<td>ID93+GLA-5E IDRI, Aeras</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Key

- Viral vector
- Mycobacterial whole cell/extract
- Protein + adjuvant

Awaiting positive signal from M72+AS01E POD or H4+IC31 POI

Likely 3 year hiatus in new large-scale clinical trials
Potential role for WHO

Advocacy for increased TB vaccine funding
preclinical (NHP) and clinical

Consensus building on portfolio priorities
(POD, POI, POR/Therapeutic)

Coordination
Pre-clinical
via Collaboration for TB Vaccine Discovery (CTVD)

Experimental medicine & portfolio management
via Global TB Vaccine Partnership (GTBVP)